SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?


To: Pat Jacks who wrote (6798)4/10/1998 12:56:00 PM
From: VLAD  Respond to of 23519
 
Pat,

For what it's worth, Pfizer claims that doses as high as 800mg did not show more adverse effects than at 100mg.

VLAD



To: Pat Jacks who wrote (6798)4/10/1998 3:12:00 PM
From: BigKNY3  Read Replies (1) | Respond to of 23519
 
Pat Jacks << On the subject of overdose of Viagra, he simply stated that because Viagra's response time was so much longer than Muse, a person might be inclined to take more and possibly overdose. Who knows what "Viagra overdose" amounts to.>>

Pat: Thanks for the reply. Leland seems to be developing his own Viagra theories of dosing and usage .Here is the statement of on overdosage from the Viagra package insert:

"Overdosage: In studies with healthy volunteers of single doses up to 800 mg, adverse events were similar to those seen at lower doses but incidence rates were increased.."

In my opinion, VVUS management marginally had the ability to market MUSE when there was no competition. Now, it is apparent that they don't have a clue in the face of an oral ED drug on the market. FDA approval of a production plant will mean nothing if there is no physician specification.

The price of VVUS will be directly related to MUSE Rxs (New and Refills) during the next three months. I would urge VVUSers to watch these numbers very carefully. VVUS will rise or fall with this market research data regardless of the success or failure of Viagra.

Good investing!

BigKNY3